Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
Persephone Biosciences, a preclinical biotech focused on microbiome-based medicines, raised $15 million in seed funding on Tuesday. The company will use the money to advance its trial for oncology therapeutics, as well as to continue developing its preventive medicine for infants.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Covid-19 stands as a litmus test for pushing the boundaries of standardized research processes. Let’s use this shared focus, urgency, and the new partnerships being forged, to invigorate and accelerate cancer research.
Developing a unique strategy backed by a strong scientific background, robust preclinical and early phase clinical data, and well-designed clinical trials will go a long way in this crowded race.